Show simple item record

dc.contributor.authorLo, Len_US
dc.contributor.authorCollins, Ien_US
dc.contributor.authorBressel, Men_US
dc.contributor.authorButow, Pen_US
dc.contributor.authorEmery, Jen_US
dc.contributor.authorKeogh, Len_US
dc.contributor.authorWeideman, Pen_US
dc.contributor.authorSteel, Een_US
dc.contributor.authorHopper, JLen_US
dc.contributor.authorTrainer, AHen_US
dc.contributor.authorMann, GBen_US
dc.contributor.authorBickerstaffe, Aen_US
dc.contributor.authorAntoniu, ACen_US
dc.contributor.authorCUZICK, JMen_US
dc.contributor.authorPhillips, K-Aen_US
dc.date.accessioned2018-10-25T10:46:36Z
dc.date.available2018-09-25en_US
dc.date.submitted2018-10-25T10:56:31.195Z
dc.identifier.citationLo LL, Collins IM, Bressel M, Butow P, Emery J, Keogh L, Weideman P, Steel E, Hopper JL, Trainer AH, Mann GB, Bickerstaffe A, Antoniou AC, Cuzick J, Phillips KA The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing JMIR Form Res 2018;2(2):e24 DOI: 10.2196/formative.9935
dc.identifier.other10.1158/1538-7445.SABCS17-P4-11-02
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/48863
dc.description.abstractBackground: iPrevent estimates breast cancer (BC) risk and provides tailored risk management information. Objective: The objective of this study was to assess the usability and acceptability of the iPrevent prototype. Methods: Clinicians were eligible for participation in the study if they worked in primary care, breast surgery, or genetics clinics. Female patients aged 18-70 years with no personal cancer history were eligible. Clinicians were first familiarized with iPrevent using hypothetical paper-based cases and then actor scenarios; subsequently, they used iPrevent with their patients. Clinicians and patients completed the System Usability Scale (SUS) and an Acceptability questionnaire 2 weeks after using iPrevent; patients also completed measures of BC worry, anxiety, risk perception, and knowledge pre- and 2 weeks post-iPrevent. Data were summarized using descriptive statistics. Results: The SUS and Acceptability questionnaires were completed by 19 of 20 clinicians and 37 of 43 patients. Usability was above average (SUS score >68) for 68% (13/19) clinicians and 76% (28/37) patients. The amount of information provided by iPrevent was reported as “about right” by 89% (17/19) clinicians and 89% (33/37) patients and 95% (18/19) and 97% (36/37), respectively, would recommend iPrevent to others, although 53% (10/19) clinicians and 27% (10/37) patients found it too long. Exploratory analyses suggested that iPrevent could improve risk perception, decrease frequency of BC worry, and enhance BC prevention knowledge without changing state anxiety. Conclusions: The iPrevent prototype demonstrated good usability and acceptability. Because concerns about length could be an implementation barrier, data entry has been abbreviated in the publicly available version of iPrevent.
dc.language.isoenen_US
dc.relation.ispartofJMIR Formative Researchen_US
dc.rightsCC BY
dc.titleAcceptability and Usability of iPrevent®, a Web-Based Tool for Assessment and Management of Breast Cancer Risk.en_US
dc.title.alternativeThe iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing
dc.typeArticle
dc.rights.holder©Louisa L Lo, Ian M Collins, Mathias Bressel, Phyllis Butow, Jon Emery, Louise Keogh, Prue Weideman, Emma Steel, John L Hopper, Alison H Trainer, Gregory B Mann, Adrian Bickerstaffe, Antonis C Antoniou, Jack Cuzick, Kelly-Anne Phillips.
dc.identifier.doi10.2196/formative.9935
pubs.issue2
pubs.notesNot knownen_US
pubs.publication-statusAccepteden_US
pubs.volume2
dcterms.dateAccepted2018-09-25en_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record